Key result
Active recurrent pericarditis is linked to a ~53% detection rate of IL-1ra autoantibodies versus remission.
Why the study?
The prevalence and role of autoantibodies targeting the endogenous IL-1 receptor antagonist in patients with recurrent pericarditis with an inflammatory phenotype were unknown.
Does the active phase of idiopathic recurrent pericarditis increase the detection of IL-1ra autoantibodies in affected patients?
Cohort (n=142)
blinded fashion
Yes
Does the active phase of idiopathic recurrent pericarditis increase the detection of IL-1ra autoantibodies in affected patients?
Transient IL-1ra autoimmunity may be a distinct feature of active recurrent pericarditis, offering potential avenues for new biomarker development and disease monitoring.
Answers are grounded in this paper and cite their sources.
IL-1ra autoantibodies may mark active recurrent pericarditis; hypothesis-generating for biomarkers and IL-1 therapies pending validation.
This cohort study investigates the prevalence and role of autoantibodies targeting the endogenous interleukin 1 (IL-1) receptor antagonist in patients with recurrent pericarditis with an inflammatory phenotype.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) conducted a cohort in Idiopathic Recurrent Pericarditis (n=142). Active recurrent pericarditis phase vs. Remission phase was evaluated on Detection of IL-1ra autoantibodies (p=<.001). The active phase of recurrent pericarditis was associated with a 53.2% detection rate of IL-1ra autoantibodies compared to 0% during remission (p<0.001).
Synapse has enriched 10 related papers. Consider them for comparative context: